Stockreport

Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

Lexicon Pharmaceuticals, Inc.  (LXRX) 
Last lexicon pharmaceuticals, inc. earnings: 4/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: lexpharma.com/investors
PDF THE WOODLANDS, Texas, March 15, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat E [Read more]